Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-01-01
|
| Series: | Drugs - Real World Outcomes |
| Online Access: | https://doi.org/10.1007/s40801-024-00477-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850197504886308864 |
|---|---|
| author | Bruno Fautrel Yoram Bouhnik Carine Salliot Franck Carbonnel Mathurin Fumery Christophe Bernardeau Yves Maugars Mathurin Flamant Fabienne Coury Ben Braithwaite Salima Hateb Janet Addison the PERFUSE investigators |
| author_facet | Bruno Fautrel Yoram Bouhnik Carine Salliot Franck Carbonnel Mathurin Fumery Christophe Bernardeau Yves Maugars Mathurin Flamant Fabienne Coury Ben Braithwaite Salima Hateb Janet Addison the PERFUSE investigators |
| author_sort | Bruno Fautrel |
| collection | DOAJ |
| format | Article |
| id | doaj-art-84039def8a8843ebb42b3d10355af2ae |
| institution | OA Journals |
| issn | 2199-1154 2198-9788 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Drugs - Real World Outcomes |
| spelling | doaj-art-84039def8a8843ebb42b3d10355af2ae2025-08-20T02:13:07ZengAdis, Springer HealthcareDrugs - Real World Outcomes2199-11542198-97882025-01-0112116316410.1007/s40801-024-00477-4Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE StudyBruno Fautrel0Yoram Bouhnik1Carine Salliot2Franck Carbonnel3Mathurin Fumery4Christophe Bernardeau5Yves Maugars6Mathurin Flamant7Fabienne Coury8Ben Braithwaite9Salima Hateb10Janet Addison11the PERFUSE investigatorsSorbonne University, AP-HP, Hôpital de La Pitié-Salpêtrière, INSERM UMRS 1136Paris IBD Center, Groupe hospitalier privé Ambroise Paré-HartmannRheumatology Department, Centre Hospitalier Universitaire d’OrléansHôpital Bicêtre, AP-HPDépartement de Gastroentérologie, CHU AmiensClinique François ChénieuxINSERM, UMR 1229, RMeS, Regenerative Medicine and Skeleton, Université de Nantes, ONIRISDépartement de Gastroentérologie, Clinique Jules VerneRheumatology Department, Lyon Sud Hospital, Hospices Civils de Lyon, University of LyonSanoïa e-Health ServicesBiogen France SAS, Gastroenterology and Rhumatologie, BiosimilarsBiogen IDEC, Clinical Research, Biosimilarshttps://doi.org/10.1007/s40801-024-00477-4 |
| spellingShingle | Bruno Fautrel Yoram Bouhnik Carine Salliot Franck Carbonnel Mathurin Fumery Christophe Bernardeau Yves Maugars Mathurin Flamant Fabienne Coury Ben Braithwaite Salima Hateb Janet Addison the PERFUSE investigators Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study Drugs - Real World Outcomes |
| title | Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study |
| title_full | Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study |
| title_fullStr | Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study |
| title_full_unstemmed | Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study |
| title_short | Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study |
| title_sort | correction real world evidence of clinical outcomes of the use of the adalimumab biosimilar sb5 in rheumatic and gastrointestinal immune mediated inflammatory diseases 12 month data from the perfuse study |
| url | https://doi.org/10.1007/s40801-024-00477-4 |
| work_keys_str_mv | AT brunofautrel correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy AT yorambouhnik correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy AT carinesalliot correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy AT franckcarbonnel correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy AT mathurinfumery correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy AT christophebernardeau correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy AT yvesmaugars correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy AT mathurinflamant correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy AT fabiennecoury correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy AT benbraithwaite correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy AT salimahateb correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy AT janetaddison correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy AT theperfuseinvestigators correctionrealworldevidenceofclinicaloutcomesoftheuseoftheadalimumabbiosimilarsb5inrheumaticandgastrointestinalimmunemediatedinflammatorydiseases12monthdatafromtheperfusestudy |